Skip to NavigationSkip to content

Business Services

FREE WEBINAR: Virtually engaged or engaged virtually?

In just over a week, on Wednesday 4 July, Pharmafocus will be collaborating with Healthcare Engagement Solutions firm Within3 to bring you a FREE webinar on the importance of virtual engagement in driving the important discussions in today’s industry.

Throughout the webinar, entitled ‘Virtually engaged or engaged virtually?’, Within3 Managing Director Andy Bowman will discuss how new technologies, including broad social media; focused private digital collaboration solutions; video conferencing and mobile messaging, are transforming the way the industry communicates.

The Brexit ‘cliff edge’: How life sciences can survive

Published on 24/06/19 at 12:01pm

Characterised by a persistent lack of clarity and a political climate that has everyone guessing from week to week, Brexit appears as an impossible challenge for industry. Partners Charlotte Tillett and Gustaf Duhs and Senior Associate Paula Harris of law firm Stevens & Bolton review the trying situation and spell out the best tactics for pharma to survive what could be a messy exit, whenever it may happen.

Top Ten most popular articles on this week

It's Friday, and time for another run-down of the week's most popular articles.

Gilead signs deal with Nurix Therapeutics worth more than $2.3 billion

Gilead has signed a deal with San Francisco biotech Nurix Therapeutics – a company focused on developing drugs that control levels of the enzyme ubiquitin E3 ligases which are responsible for the breakdown of proteins in human cells.

Dysregulated and/or mutated proteins play a central role in the development and progression of many human diseases. It is hoped that by controlling protein levels Nurix’s technologies will be able to tackle cancer and other challenging diseases.

GSK launch sale of consumer healthcare brands

British multinational GlaxoSmithKline (GSK) has launched a sale of some of its consumer healthcare brands.

The sale comes as GSK seeks to raise £1 billion before it folds its consumer healthcare business into a joint venture with American drugmaker Pfizer.

GSK has thus bundled together three different portfolios which it will sell off to the highest bidder. The firm has roped in boutique investment bank Greenhill to market the portfolios which include Latin American drugs and Physiogel Skin Care products.

No-deal Brexit could cause shortages and higher prices, healthcare distributors warn

The Healthcare Distribution Association (HDA) has warned MPs that Britain could face shortages of medicines if it were to leave the European Union (EU) without a deal on 31 October.

Supplies of short-life and less common medicines would be put at risk in a no-deal Brexit, according to representatives of the HDA speaking to parliament’s Brexit select committee on 19 June.

The missing link: Blockchain in clinical data management

Published on 14/06/19 at 10:59am

Louis Goss explores the potential uses for the much-hyped technology blockchain as a tool to tackle the data management challenges faced by the pharmaceutical and life sciences industries

On 10 February 1996, the supercomputer Deep Blue checkmated world champion chess player Garry Kasparov. The two-hour game became the first instance of a reigning world champion being beaten by a machine.

Having lost the first game, the Russian grandmaster did manage to win out overall, beating IBM’s original Deep Blue computer 4-2 in a match of six games.

Top Ten most popular articles on this week!

Pfizer supressed research showing their arthritis drug Enbrel reduced the risk of Alzheimer’s. This was the big revelation this week! The story prompted calls for greater transparency and more open science as researchers were outraged that such important findings could be suppressed.

Meanwhile MPs in the House of Commons discussed using Crown Use licensing rules to break Vertex’s IP rights over Orkambi. The discussion marked a new stage in the longstanding stale mate between the US firm and the British government.

GSK tech exec joins Institute of Cancer Research

Published on: 13/06/19

The Institute of Cancer Research (ICR) has said GlaxoSmithKline’s Dr Adrian Cottrell will join as the institute’s new Chief Information Officer.

In his new role Dr Cottrell will lead the institute’s information and communication technologies as the academic research organisation sets up a new and innovative IT infrastructure for research.

As one of the worlds’ leading academic organisations conducting research into cancer the ICR is a pioneer of big data, machine learning and artificial intelligence (AI).

Catalyst Pharma sues FDA after agency approves Jacobus' LEMS drug

Florida firm Catalyst Pharmaceuticals is suing the FDA after the agency approved a rival’s drug.

The lawsuit alleges the approval of Jacobus Pharmaceutical’s Lambert-Eaton Myasthenic Syndrome (LEMS) drug Ruzurgi (amifampridine) infringes on Catalyst’s drug Firdapse’s right to market exclusivity.

Jacobus claim that Ruzurgi will compete with Firdapse through being prescribed off-label. Firdapse costs twice as much as Ruzurgi.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches